Introduction: The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI-3, which began on August 1, 2016, is a 5-year renewal of the current ADNI-2 study.
Methods: ADNI-3 will follow current and additional subjects with normal cognition, mild cognitive impairment, and AD using innovative technologies such as tau imaging, magnetic resonance imaging sequences for connectivity analyses, and a highly automated immunoassay platform and mass spectroscopy approach for cerebrospinal fluid biomarker analysis. A Systems Biology/pathway approach will be used to identify genetic factors for subject selection/enrichment. Amyloid positron emission tomography scanning will be standardized using the Centiloid method. The Brain Health Registry will help recruit subjects and monitor subject cognition.
Results: Multimodal analyses will provide insight into AD pathophysiology and disease progression.
Discussion: ADNI-3 will aim to inform AD treatment trials and facilitate development of AD disease-modifying treatments.
Keywords: Alzheimer's disease; Amyloid phenotyping; Brain Health Registry; Centiloid method; Clinical trial biomarkers; Functional connectivity; Tau imaging.
Copyright © 2016 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.